Last reviewed · How we verify
Sphenopalatine Ganglion Block
Sphenopalatine Ganglion Block is a Small molecule drug developed by University Hospital, Clermont-Ferrand. It is currently FDA-approved for Acute migraine headache, Cluster headache, Trigeminal neuralgia. Also known as: SGB.
A sphenopalatine ganglion block is a minimally invasive procedure that interrupts pain signals by anesthetizing the sphenopalatine ganglion, a parasympathetic nerve cluster in the pterygopalatine fossa.
A Sphenopalatine Ganglion Block (SPGB) is a medical intervention used to treat various conditions, including Temporomandibular Disorder, Septum Deviation, Post-Dural Puncture Headache, and Headache, as per studies listed on ClinicalTrials.gov. The exact mechanism of SPGB is unknown, according to ChEMBL.
At a glance
| Generic name | Sphenopalatine Ganglion Block |
|---|---|
| Also known as | SGB |
| Sponsor | University Hospital, Clermont-Ferrand |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
The sphenopalatine ganglion is a key relay station for parasympathetic innervation to the head and face. By delivering local anesthetic directly to this ganglion via transnasal or other approaches, the procedure blocks pain transmission associated with headaches and facial pain conditions. This interruption of autonomic signaling provides rapid pain relief, particularly for acute migraine and cluster headache attacks.
Approved indications
- Acute migraine headache
- Cluster headache
- Trigeminal neuralgia
- Chronic headache and facial pain
Common side effects
- Transient nasal discomfort or congestion
- Epistaxis (nosebleed)
- Temporary numbness or tingling in nasal/palatal region
- Headache recurrence after procedure
Key clinical trials
- Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial (NA)
- Postop Pain Management in Pituitary Tumour Patients (PHASE4)
- Efficacy of Sphenopalatine Block Compared to Blood Patch in the Management of Post-dural Puncture Headaches (PHASE3)
- Dexamethasone vs Dexmedetomidine in Sphenopalatine Ganglion Block for Rhinoplasty Pain (PHASE1)
- Functional Endoscopic Sinus Surgery Study (PHASE1, PHASE2)
- Transnasal Sphenopalatine Ganglion Block for Postoperative Pain and Recovery in Tonsillectomy (TONwoPA) (NA)
- Infraorbital-Infratrochlear Block vs Sphenopalatine Ganglion Block for Postoperative Analgesia in Septorhinoplasty. (NA)
- Sphenopalatine Block vs Dexmedetomidine Infusion in Trans Nasal Endoscopic Pituitary Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sphenopalatine Ganglion Block CI brief — competitive landscape report
- Sphenopalatine Ganglion Block updates RSS · CI watch RSS
- University Hospital, Clermont-Ferrand portfolio CI
Frequently asked questions about Sphenopalatine Ganglion Block
What is Sphenopalatine Ganglion Block?
How does Sphenopalatine Ganglion Block work?
What is Sphenopalatine Ganglion Block used for?
Who makes Sphenopalatine Ganglion Block?
Is Sphenopalatine Ganglion Block also known as anything else?
What development phase is Sphenopalatine Ganglion Block in?
What are the side effects of Sphenopalatine Ganglion Block?
Related
- Manufacturer: University Hospital, Clermont-Ferrand — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Acute migraine headache
- Indication: Drugs for Cluster headache
- Indication: Drugs for Trigeminal neuralgia
- Also known as: SGB
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing